Meclofenamate for Brain Cancer

Recruiting in Palo Alto (17 mi)

+7 other locations

Overseen byAdrienne Boire, MD, PhD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Memorial Sloan Kettering Cancer Center

No Placebo Group

Trial Summary

What is the purpose of this trial?

Cancer that has spread to the brain, or brain metastasis, is difficult to treat. Meclofenamate is a drug which has been shown to reduce brain metastasis growth in the laboratory. This medicine has been used in the past to treat pain. But, in this study, it will be used to prevent new brain metastasis. This is the first time that meclofenamate will be used in patients with brain metastasis. This is a pilot study which means that the purpose of this study is to determine if a larger clinical trial of meclofenamate is possible in patients with brain metastasis. This study also aims to find out what effects, good and/or bad meclofenamate has on the patient and the cancer that has spread to the brain. The investigators also want to learn more about potential effects that this drug may have in the digestive system.

Research Team

Adrienne Boire, MD, PhD

Principal Investigator

Memorial Sloan Kettering Cance Center

Eligibility Criteria

This trial is for adults aged 18-80 with recurrent or progressive brain metastasis from solid tumors, visible on MRI. Participants must have a stable systemic disease or no evidence of disease and can't be pregnant, have had recent surgery, active bleeding issues, severe allergies to NSAIDs like meclofenamate, certain heart conditions, uncontrolled systemic cancer growth, or poor kidney/liver function.

Inclusion Criteria

I may have multiple brain metastases.

I have had surgery or SRS for some, but not all, of my recurrent cancer lesions.

Systemic disease must be well-controlled or NED in the opinion of the patient's primary oncologist

See 4 more

Exclusion Criteria

My cancer has spread to the lining of my brain and spinal cord.

Platelet count ≤ 70,000/mm3

International normalized ratio (INR) > 1.6 and a Partial Thromboplastin Time (PTT) > 40 seconds

See 18 more

Treatment Details

Interventions

Meclofenamate (Nonsteroidal Anti-inflammatory Drug)

Trial OverviewThe study tests Meclofenamate's effectiveness in preventing new brain metastases in patients whose cancer has spread to the brain. It's a pilot study aimed at seeing if larger trials are feasible and understanding the drug's impact on both the patient and their brain metastasis.

Participant Groups

1Treatment groups

Experimental Treatment

Group I: MeclofenamateExperimental Treatment1 Intervention

All enrolled patients will receive the study drug, meclofenamate at 100 mg PO BID.